Nob Hill Therapeutics

Nob Hill Therapeutics is a New Mexico-based biotechnology company focused on improving respiratory patient care through innovative drug delivery technology. Their flagship product, the DryNeb dry powder nebulizer, is a patented technology designed to deliver drugs to the lungs with higher efficiency than current dry powder inhalers. The DryNeb can deliver high doses of pure active ingredient and is being developed as a platform technology for various pulmonary-related diseases, including Lower Respiratory Track Infections, Cystic Fibrosis, and Lung Cancer.

Nob Hill Therapeutics is a dynamic and growing company with a highly qualified and experienced team, a strong advisory board, and significant investment backing. They have secured funding through a Series A financing round, received multiple HHS Phase II grants, and participated in industry events like the Respiratory Innovation Summit. Their commitment to developing new technologies and therapies for lung-related diseases reflects their dedication to improving the lives of patients facing respiratory challenges.

Nob Hill Therapeutics is a company dedicated to improving patients' lives by re-imagining inhalation medicines and their delivery methods. Their focus is on developing new technologies and therapies for lung-related diseases that are difficult to treat effectively with current methods, with the ultimate goal of changing the treatment paradigm for high-dose lung delivery.

Nob Hill Therapeutics promotes a culture of collaboration, results-driven action, and rapid progress. They value pragmatism, trust, and doing the right thing, emphasizing teamwork and mutual support. This is evident in their commitment to building a highly qualified and experienced team, their involvement in the VIC Technology Venture Development ecosystem, and their focus on developing innovative respiratory technologies to improve patient lives.